A new study recently published in the journal Respiratory Research revealed that a uridine-based therapy can improve pulmonary fibrosis symptoms in a mouse model. The study is entitled “Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis,” and was…
A team of researchers from the Department of Clinical and Experimental Medicine at the University of Catania, Italy recently reviewed the co-occurrence of additional diseases in Idiopathic Pulmonary Fibrosis and their current therapeutic strategies. The study, entitled “IPF, comorbidities and management implications,“ was published in the Sarcoidosis Vasculitis and…
The National Institutes of Health (NIH) recently awarded a Yale University scientist with a $3 million dollar research grant to help fund his work on exploring the molecular networks that underlie the histological features of idiopathic pulmonary fibrosis (IPF). The research project hopes to offer new insights into the disease and lead to the discovery…
Reata Pharmaceuticals recently announced that results of a Phase 2 study of bardoxolone methyl in patients suffering from pulmonary arterial hypertension (PAH) will be presented at the 2015 American College of Chest Physicians (CHEST) annual meeting at the Palais des Congrès de Montréal, Canada. The presentation, entitled “Initial Data Report from…
In a newly published paper in the Stem Cells Translational Medicine journal entitled Adult Lung Spheroid Cells Contain Progenitor Cells and Mediate Regeneration in Rodents With Bleomycin-Induced Pulmonary Fibrosis, scientists from North Carolina State University discovered a quick and simple method to produce stem…
MediciNova, Inc., a biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the US Food and Drug Administration has granted its leading product candidate for idiopathic pulmonary fibrosis (IPF) a Fast Track Designation. This follows the agency’s October 2014 decision to grant…
Promedior recently announced the initiation of a Phase 2 trial of PRM-151, an experimental anti-fibrotic agent, in patients with Idiopathic Pulmonary Fibrosis (IPF). Previous clinical Phase 1 studies also conducted by Promedior, a biotechnology company working on therapeutics for the treatment of fibrosis, led to this placebo-controlled Phase 2 study, which…
In a recent paper published in the Proceedings of the National Academy of Sciences of USA entitled “DC-SIGN activation mediates the differential effects of SAP and CRP on the innate immune system and inhibits fibrosis in mice,” scientists from Texas A&M University…
In a recent study published in the journal Proceedings of the National Academy of Sciences (PNAS), a team of researchers from Columbia Engineering and Columbia University Medical Center (CUMC) have developed a new strategy for delivering small volumes of drug agents into the lungs. Effective treatment strategies for…
The Pulmonary Fibrosis Foundation (PFF) recently launched an awareness campaign highlighting that September is Global Pulmonary Fibrosis Awareness Month. In order to lead the celebration, the PFF has planned several activities throughout the month that aim to not only support disease education for patients, family members and professionals, but also raise funds to support scientific…
Get regular updates to your inbox.
